Expression data from syngeneic Hepa1-6 model in C57Bl/6J mice

Lenvatinib is an effective drug in advanced hepatocellular carcinoma (HCC). Its combination with the anti-PD1 immune checkpoint inhibitor pembrolizumab has achieved encouraging results in phase Ib and is currently being tested in phase III trials. Here, we aimed at exploring the molecular and immunomodulatory effects of lenvatinib alone or in combination with anti-PD1. We generated a syngeneic model of HCC in C57BL/6J mice and randomized the animals to receive placebo, lenvatinib, anti-PD1 or combination treatment. Transcriptomic analysis were performed to assess the expression profile of tumors from mice receiving each treatment strategy. Tumors were collected 13 days post-randomization. Animals were euthanized 1 day after the last anti-PD1 dose and 2h after the last lenvatinib dose in accordance with pharmacodynamic studies (n=21). Gene expression analyses were conducted using the Clariom S Mouse Array (Affymetrix).